Novelix Pharmaceuticals Ltd (NOVELIX) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Novelix Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve unaudited standalone ....
Intimation · 11 Nov 2026, 5:30 am
Novelix Pharmaceuticals Board Meeting Scheduled for 11th Nov'26 Novelix Pharmaceuticals Limited has scheduled a Board of Directors meeting on 11th Nov'26 to consider and approve the unaudited standalone financial results for the quarter and half-year ended 30th Sep'26, alongside the auditor's limited review report. In accordance with SEBI Insider Trading regulations, the trading window for designated persons and their immediate relatives has been closed effective 1st Oct'26 and will reopen 48 hours post the conclusion of the board meeting.
Attached
Change in Management · 03 Oct 2026, 12:47 am
Novelix Pharmaceuticals Approves Appointment of Gnana Prakash Gattu as Whole-Time Director Novelix Pharmaceuticals Limited announced that its shareholders, at the 32nd Annual General Meeting held on 30th Sep'26, approved the appointment of Mr. Gnana Prakash Gattu as Whole Time Director for a 5-year tenure effective 29th Aug'26. Mr. Gattu, an IIT Chennai graduate with over 25 years of experience across management and information technology, belongs to the promoter group and holds no relationships with other directors or key managerial personnel.
Attached
Annual General Meeting · 02 Oct 2026, 12:47 am
Novelix Pharmaceuticals Shareholders Approve All 32nd AGM Resolutions With Majority Novelix Pharmaceuticals announced that shareholders approved all three resolutions at its 32nd AGM held on 30th Sep'26 with requisite majorities. With 66.57% total voter turnout (18,952,011 polled votes out of 28,470,000 shares), each resolution received 99.97% valid votes in favor (18,946,001 votes) and 0.03% against (6,010 votes). The passed agenda comprises the adoption of standalone audited financial statements for FY ended 31st Mar'26, the re-appointment of retiring Non-Executive Director Ms. Sridevi Belide, and the appointment of Mr. Gnana Prakash Gattu as Whole Time Director.
Submission of Voting results & Scrutinizers Report.
Annual General Meeting · 02 Oct 2026, 12:46 am
Novelix Pharmaceuticals Shareholders Approve All Resolutions at 32nd AGM Novelix Pharmaceuticals Limited announced the voting results for its 32nd AGM held on 30th Sep'26, with all three resolutions securing requisite shareholder approval. Total turnout stood at 66.57% (18,952,011 votes polled out of 28,470,000 shares), with 99.97% of polled votes in favor across all items. Passed resolutions include the adoption of standalone audited financial statements for the year ended 31st Mar'26, the re-appointment of Ms. Sridevi Belide as Non-Executive Director, and a special resolution approving the appointment of Mr. Gnana Prakash Gattu as Whole Time Director.
Submission of Outcome of the 32nd Annual General Meeting.
Annual General Meeting · 30 Sept 2026, 11:49 pm
Attached.
Annual General Meeting · 08 Sept 2026, 3:52 am
Novelix Pharmaceuticals Schedules 32nd AGM and Issues FY26 Annual Report Access Notice Novelix Pharmaceuticals Limited will convene its 32nd Annual General Meeting on 30th Sep'26 at 3:00 PM IST via video conferencing and audio-visual means. Pursuant to SEBI Listing Regulations, the company issued web access details for its FY26 Annual Report and AGM Notice to shareholders without registered email addresses. The company also reminded physical security holders to complete mandatory KYC updates—including PAN, bank details, and nominations—and encouraged dematerialization of shares in compliance with SEBI directives through its Registrar and Share Transfer Agent, Venture Capital and Corporate Investments.
Attached.
Annual General Meeting · 08 Sept 2026, 3:49 am
Novelix Pharmaceuticals Convenes 32nd AGM and Proposes Key Board Appointments Novelix Pharmaceuticals has scheduled its 32nd AGM for 30th Sep'26 via video conferencing. Key agenda items include adopting standalone audited financial statements for FY25–26 and approving the re-appointment of Non-Executive Director Ms. Sridevi Belide, who retires by rotation. Additionally, the company seeks shareholder approval via special resolution to appoint Mr. Gnana Prakash Gattu as Whole-Time Director for a five-year term from 29th Aug'26 to 28th Aug'31. The remote e-voting cut-off date is set for 23rd Sep'26, with voting running from 27th Sep'26 to 29th Sep'26.
Submission of annual report for the financial year ended March 31, 2026.
Others (Uncategorized) · 08 Sept 2026, 3:46 am
Submission of Intimation of AGM Date.
Annual General Meeting · 31 Aug 2026, 6:07 pm
Submission of intimation of change in Designation of Director.
Change in Management · 31 Aug 2026, 6:04 pm
Novelix Pharmaceuticals Appoints Promoter Group Member as Whole-time Director Novelix Pharmaceuticals appointed Mr. Gnana Prakash Gattu as a Whole-time Director, effective 29th Aug'26, for a five-year term, pending shareholder approval. Mr. Gattu belongs to the company's Promoter and Promoter group but is not related to any other Directors or KMP. He is a graduate from IIT-Chennai with over 25 years of experience in management and information technology. The appointment was approved by the Board in a meeting held on 29th Aug'26. He is not debarred by SEBI.
Submission of outcome of the board meeting.
Outcome · 29 Aug 2026, 11:32 pm
Novelix Board Meeting: AGM Dates and Director Appointment Novelix Pharmaceuticals' board approved the financial year-end Mar 31, '26 report. The 32nd AGM will be held via video conference on Sep 30, '26. The record date for AGM e-voting eligibility is Sep 23, '26, with share transfer books closed from Sep 24 to Sep 30, '26. Gnana Prakash Gattu (DIN:00517921) was appointed as a Whole-time Director effective Aug 29, '26, for a 5-year term, subject to shareholder approval. Mr. Gattu belongs to the Promoter group.
Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2026 ,inter alia, to consider and approve Submission of Prior ....
Intimation · 25 Aug 2026, 11:38 pm
Novelix Pharma Board Meeting to Discuss Director Appointment and AGM Details Novelix Pharmaceuticals has scheduled a Board of Directors meeting for 29th Aug'26. Key agenda items include approving the notice for the 32nd Annual General Meeting and the Board Report for the financial year ended 31st Mar'26. The board will also consider and approve the appointment of Mr. Gnana Prakash Gattu (DIN: 00517921) as a Whole-Time Director. This notice was filed with the BSE on 25th Aug'26.
Submission of Intimation of Land Lease Deed.
Others (Uncategorized) · 20 Aug 2026, 6:51 pm
Novelix Pharma Leases Land for Micro Algae Cultivation from Promoter Group Entity Novelix Pharmaceuticals executed a 5-year land lease deed on 19th Aug'26 for 0.925 acres in Telangana to establish facilities for Micro Algae Cultivation and Glass Reactor Systems. The agreement involves a monthly rent of Rs. 5,000, with a 5% increase every three years. The lessor, Mr. Gnana Prakash Gattu, is a non-executive director and part of the promoter group. The company has stated the transaction was conducted on an arm's length basis, aiming to develop its micro algae business.
Submission of Statement of Deviation & Variation
Others (Uncategorized) · 14 Aug 2026, 12:19 am
Novelix Pharma: No Deviation in Fund Utilization for Q1FY27 Novelix Pharmaceuticals confirmed no deviation in the utilization of funds for the quarter ended 30th Jun'26. The company had raised Rs. 421.50 lakhs on 29th May'26 through public/rights/preferential issues. As of the quarter-end, the entire amount was fully utilized for its stated objectives of meeting long-term funding, working capital needs, and general corporate purposes. The audit committee reviewed the statement on 13th Aug'26, noting no deviation, and there were no adverse comments from auditors.
Submission of financial Results for the quarter ended 30th June, 2026.
Financial Result · 14 Aug 2026, 12:08 am
Novelix Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 3,691 (+65.2% YoY | +46.5% QoQ) ■ EBITDA: 130 (+620.3% YoY | +2.4% QoQ) ■ EBITDA Margin (%): 3.5 (+271 bps YoY | -152 bps QoQ) ■ PAT: 118 (+1001.8% YoY | +29.3% QoQ) ■ EPS (INR): 0.49 (+345.5% YoY | +53.1% QoQ)
Submission of outcome of the Board meeting.
Outcome · 13 Aug 2026, 11:42 pm
Novelix Pharma Reports Strong Q1 FY27 Profit Growth Novelix Pharmaceuticals (NOVELIX) reported strong Q1 FY27 results, with net profit surging to ₹117.89 lakh from ₹10.70 lakh YoY, an increase of over 10x. Revenue from operations for the quarter ended 30th Jun'26 grew 65% YoY to ₹3,691.39 lakh. Sequentially, revenue rose 46.5% QoQ, while net profit increased 29.3% from ₹91.19 lakh in the prior quarter. Basic EPS for Q1 was ₹0.49, compared to ₹0.09 in the same quarter last year. The results were approved on 13th Aug'26.
Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Submission of prior ....
Intimation · 13 Aug 2026, 5:30 am
Novelix Pharma Board Meeting to Approve Q1FY27 Results on 13th Aug'26 Novelix Pharmaceuticals has scheduled a Board of Directors meeting on 13th Aug'26 to consider and approve its unaudited standalone financial results for the quarter ending 30th Jun'26. The company also announced the closure of its trading window for designated persons from 01st Jul'26 until 48 hours after the meeting's conclusion.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vupparapalli Chandrasekhar Reddy & Others
Acquisition/ Disposal of Shares · 14 Jul 2026, 1:11 am
Novelix Pharma Promoter Converts Warrants, Increases Stake Promoter group member Vupparapalli Chandrasekhar Reddy was allotted 775,000 equity shares in Novelix Pharmaceuticals on 09th Jul'26, following the conversion of warrants from a preferential allotment. This acquisition represents a 1.29% stake. Post-allotment, Reddy's individual holding increased from 8.92% to 10.21%. The combined holding of the acquirer and Persons Acting in Concert (PACs) rose from 11.95% to 12.75% of the total share capital. The company's total issued equity share capital increased post-conversion.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srinidhi Fine - Chemicals LLP & Others
Acquisition/ Disposal of Shares · 14 Jul 2026, 1:02 am
Promoter Group Increases Stake in Novelix Pharma via Warrant Conversion Promoter group entities, Srinidhi Fine-Chemicals LLP and Narahari Belide, have increased their stake in Novelix Pharmaceuticals. On 09 Jul'26, they acquired 25,00,000 equity shares via warrant conversion on a preferential basis. This acquisition raised their combined holding from 36.42% to 39.35% of the post-issue capital. Following the allotment, Srinidhi Fine-Chemicals' stake increased to 35.13% and Narahari Belide's to 4.21%. The company's total issued equity capital consequently expanded from 23,895,000 to 28,470,000 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gattu Gnana Prakash & Others
Acquisition/ Disposal of Shares · 14 Jul 2026, 1:00 am
Novelix Pharma: Promoter Group Acquires Shares via Warrant Conversion Neha Gattu of Novelix Pharmaceuticals' promoter group acquired 100,000 equity shares on 09th Jul'26 following the conversion of warrants from a preferential allotment. This transaction increased her individual holding from nil to 100,000 shares, representing a 0.35% stake. Post-acquisition, the total holding of the promoter group (Gattu Gnana Prakash, Arati Gattu, and Neha Gattu) increased from 600,000 shares (2.51% diluted) to 700,000 shares, although their combined final holding percentage was not explicitly stated in the filing.
Submission of Intimation under regulation 7(2) of SEBI (PIT) Regulations, 2015.
Others (Uncategorized) · 14 Jul 2026, 12:09 am
Novelix Promoters Increase Stake via Preferential Allotment Novelix Pharmaceuticals' promoters and promoter group acquired additional equity shares on 09-Jul'26 through a preferential offer. Promoter entity Srinidhi Fine Chemicals LLP acquired 2.1M shares, increasing its stake from 33.07% to 35.13%. Promoter Vupparapalli Chandrasekhar Reddy acquired 775,000 shares, boosting his holding from 8.92% to 10.21%. Other promoter group members also participated, including Narhari Belide who acquired 400,000 shares, raising his stake to 4.21%. The company was informed of these transactions on 11-Jul'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gattu Gnana Prakash & Others
Acquisition/ Disposal of Shares · 13 Jul 2026, 6:35 pm
Novelix Pharma: Promoter Group Member Acquires Shares via Warrant Conversion Neha Gattu, a member of the promoter group, acquired 100,000 equity shares (0.35% stake) in Novelix Pharmaceuticals on 09th Jul'26. The acquisition resulted from the conversion of warrants issued via a preferential allotment. Following this transaction, Neha Gattu's shareholding increased from 0 to 100,000 shares, representing 0.35% of the post-acquisition voting capital. The combined holding of the acquirer and Persons Acting in Concert (PACs) now stands at 600,000 shares, or a 2.11% stake in the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srinidhi Fine-Chemicals LLP & Narahari Belide
Acquisition/ Disposal of Shares · 11 Jul 2026, 9:01 pm
Novelix Pharma: Promoter Group Increases Stake via Warrant Conversion Promoter group entities Srinidhi Fine-Chemicals LLP and Narahari Belide increased their aggregate holding in Novelix Pharmaceuticals (NOVELIX) on 09th Jul'26. The acquisition of 2.1M and 400k shares respectively was via conversion of warrants issued on a preferential basis. Post-conversion, Srinidhi Fine-Chemicals' stake is 35.13% and Narahari Belide's is 4.21%. The combined promoter group holding rose from 36.42% to 39.35% of the total share capital. The company's equity share capital increased to Rs. 28.47 Cr post-allotment.
Submission of intimation of allotment of equity shares.
Others (Uncategorized) · 10 Jul 2026, 6:31 pm
Novelix Pharmaceuticals Allots Equity Shares via Warrant Conversion and Private Placement On 09 Jul'26, Novelix Pharmaceuticals' board approved two equity allotments. First, 33,75,000 shares were issued at Rs. 20 each to the promoter group upon conversion of warrants. The company received the remaining 75% consideration of Rs. 5.06 crore. Second, 12,00,000 shares were allotted to non-promoters via a preferential private placement at Rs. 57 per share, raising Rs. 6.84 crore. Post-allotment, the company's paid-up equity capital increased to Rs. 28.47 crore from Rs. 23.90 crore.
Submission of outcome of Board Meeting.
Others (Uncategorized) · 10 Jul 2026, 12:57 am
Novelix Pharma Board Approves Allotment of Equity via Warrants and Preferential Issue On 09 Jul'26, Novelix Pharma’s board approved two equity allotments. Firstly, 33.75 lakh shares at Rs. 20 each to the promoter group upon warrant conversion, raising Rs. 6.75 crore. Secondly, a preferential allotment of 12 lakh shares at Rs. 57 each to non-promoters through a private placement, raising Rs. 6.84 crore. The total capital infusion is Rs. 13.59 crore. Post-allotment, the paid-up equity capital will increase from Rs. 23.90 crore to Rs. 28.47 crore.